All In Biotech

Drug Trial Radar · NCT02367638

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Apr 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Planned (sponsor's estimate)

Start

Mar 2015

Primary completion

Jul 2015

Sponsor

Lead sponsor
Green Cross CorporationIndustry
Sponsor type
Industry
First posted
Feb 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
Who can join
All sexes, from 20 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults.

Conditions

  • Varicella (Chicken Pox)

Interventions

  • MG1111Biological

    Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection

  • VARIVAXBiological

    VARIVAX is administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the solicited adverse events and unsolicited adverse events during 7 days after vaccinationTime frame: 7 days
  2. To evaluate the unsolicited adverse events during 42 days after vaccinationTime frame: 42 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.